RESMED INC News
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
see moreRESMED INC Market News
4d
ResMed Dip: CEO Sale, Baird Cuts Price Target Now!
- ResMed (RMD) slipped after CEO Michael J. Farrell sold nearly 5,000 shares and Robert W. Baird lowered its price target. This article breaks down the March 11 sell-off, recent analyst movements and the dividend context to help investors weigh near-term noise against underlying fundamentals.
18d
ResMed RMD: Quiet Week, Small Volatility - Update!
ResMed (RMD) saw modest volatility last week with a notable dip on Feb 24 and a partial rebound on Feb 26. There were no material corporate, regulatory, or earnings developments during the period; price moves reflected short-term trading rather than new fundamental information. The company’s durable respiratory-care franchise and progress in AI-enabled devices continue to underpin investor confidence.
25d
ResMed Strengthens Margins; RMD Risks Rise—Q2 Beat
ResMed reported a strong Q2 with revenue up 11%, expanding margins and a $600M+ buyback plan, but near-term headwinds from GLP‑1 therapies, trade probes and competitive shifts inject caution for RMD in the S&P 500.
17 Feb at 14:36
ResMed Drops After Philips Return Fears; EPS Beat
ResMed shares fell mid‑week after analyst concerns about Philips re‑entering the U.S. CPAP market, despite ResMed posting a beat on Q2 FY2026 EPS and revenue. Diverging analyst price targets and strong underlying fundamentals created the volatility.
10 Feb at 14:37
RMD Rally: ResMed Up 9% on Renewed Investor Flows!
ResMed (RMD) staged a four-day rebound in early February, climbing from $251.41 to $275.96 as trading volumes ran above 50‑day averages. No new company‑specific catalysts were reported during the week; the move appears driven by investor re-entry and sector strength ahead of potential upcoming corporate events.